AGMB (AgomAb Therapeutics NV) Earnings Power Value (EPV): $2.77 (As of Dec25)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Earnings Power Value (EPV)?

AgomAb Therapeutics NV AGMB +0.85% 14 Earnings Power Value (EPV) is $2.77 as of Dec25. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

As of Dec25, AgomAb Therapeutics NV's earnings power value is $2.77. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


AgomAb Therapeutics NV  (NAS:AGMB) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


AgomAb Therapeutics NV Earnings Power Value (EPV) Related Terms


AgomAb Therapeutics NV Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Earnings Power Value (EPV) Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
0.00 0.00 0.00 0.00 0.00

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Earnings Power Value (EPV) Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

AGMB vs DNA, ACRS, RLMD: Earnings Power Value (EPV) Comparison

For the Biotechnology subindustry, AgomAb Therapeutics NV's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AgomAb Therapeutics NV Earnings Power Value (EPV) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where AgomAb Therapeutics NV's Earnings Power Value (EPV) falls into.


AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

What does a Earnings Power Value (EPV) of $2.77 mean?
AgomAb Therapeutics NV (AGMB) has a Earnings Power Value (EPV) of $2.77 as of Dec25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Earnings Power Value (EPV) too high?
AgomAb Therapeutics NV's current Earnings Power Value (EPV) is $2.77. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Earnings Power Value (EPV) compare to DNA and ACRS?
AgomAb Therapeutics NV's Earnings Power Value (EPV) of $2.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Earnings Power Value (EPV) is $2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Earnings Power Value (EPV) of $2.77. The current Earnings Power Value (EPV) is $2.77. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Earnings Power Value (EPV) is $2.77 as of Dec25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price